NCT04723069View on ClinicalTrials.gov

Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions
Pelvic Inflammatory Disease
Interventions
DRUG

Control Group

metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.

DRUG

Test Group

metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.

Trial Locations (1)

75270

Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi, Karachi

All Listed Sponsors
collaborator

Zhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou, China

UNKNOWN

collaborator

Center for bioequivalence studies and Clinical Research (CBSCR), ICCBS, University of Karachi

UNKNOWN

lead

University of Karachi

OTHER

NCT04723069 - Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases | Biotech Hunter | Biotech Hunter